Skip to main content


  • Oral presentation
  • Open Access

O121. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 15,
  • 16,
  • 17,
  • 18,
  • 11,
  • 19 and
  • 20
Journal of the International AIDS Society201013 (Suppl 4) :O7

  • Published:


  • Consensus Statement
  • European Guideline
  • Maraviroc
  • CCR5 Antagonist
  • Limited Therapeutic Option


Testing for HIV tropism is recommended before prescribing a chemokine receptor blocker. To date, in most European countries HIV tropism is determined using a phenotypic test. Recently, new data have emerged supporting the use of a genotypic HIV V3-loop sequence analysis as the basis for tropism determination. The European guidelines group on clinical management of HIV-1 tropism testing was established to make recommendations to clinicians and virologists.


We searched online databases for articles from Jan 2006 until March 2010 with the terms: tropism or CCR5-antagonist or CCR5 antagonist or maraviroc or vicriviroc. Additional articles and/or conference abstracts were identified by hand searching. This strategy identified 712 potential articles and 1240 abstracts. All were reviewed and finally 57 papers and 42 abstracts were included and used by the panel to reach a consensus statement.


The panel recommends HIV-tropism testing for the following indications: i) drug-naïve patients in whom toxicity or limited therapeutic options are foreseen; ii) patients experiencing therapy failure whenever a treatment change is considered. Both the phenotypic Enhanced Trofile assay (ESTA) and genotypic population sequencing of the V3-loop are recommended for use in clinical practice. Although the panel does not recommend one methodology over another it is anticipated that genotypic testing will be used more frequently because of its greater accessibility, lower cost and shorter turnaround time. The panel also provides guidance on technical aspects and interpretation issues. If using genotypic methods, triplicate PCR amplification and sequencing testing is advised using the G2P interpretation tool (clonal model) with an FPR of 10%. If the viral load is below the level of reliable amplification, proviral DNA can be used, and the panel recommends performing triplicate testing and use of an FPR of 10%. If genotypic DNA testing is not performed in triplicate the FPR should be increased to 20%.


The European guidelines on clinical management of HIV-1 tropism testing provide an overview of current literature, evidence-based recommendations for the clinical use of tropism testing and expert guidance on unresolved issues and current developments. Current data support both the use of genotypic population sequencing and ESTA for co-receptor tropism determination. For practical reasons genotypic population sequencing is the preferred method in Europe.

Authors’ Affiliations

Ghent University Hospital, Infectious Diseases Unit, Ghent, Belgium
University Medical Center Utrecht, Dept of Virology, Medical Microbiology, Utrecht, Netherlands
University of Cologne, Institute of Virology, Cologne, Germany
Bichat-Claude Bernard University Hospital, Laboratoire de Virologie, Paris, France
IRSICAIXA Foundation, Retrovirology Laboratory, Badalona, Spain
Catholic University Rome, Istituto di Clinica delle Malattie Infettive, Rome, Italy
EATG, Berlin, Germany
Hospital Universitario San Cecilio, Granada, Spain
Royal Free Hampstead NHS Trust and UCL Medical School, Dept of Virology, London, UK
University of Basel, Dept of Biomedicine, Inst of Medical Microbiology, Basel, Switzerland
University of Erlangen, Institute of Clinical and Molecular Virology, Erlangen, Germany
CHU de Bordeaux, Laboratoire de Virologie, Bordeaux, France
University of Rome Tor Vergata, Dept of Experimental Medicine, Rome, Italy
Sheba Medical Center, National Hemophilia Center, Tel Aviv, Israel
Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
Karolinska University Hospital, Div of Infectious Diseases and Clinical Virology, Stockholm, Sweden
Rega Institute and University Hospitals, Lab. for Clinical and Epidemiological Virology, Leuven, Belgium
University Hospital Ghent, AIDS reference laboratory, Ghent, Belgium
University of Siena, Department of Molecular Biology, Siena, Italy
Erasmus Medical Center, Dept of Virology, Rotterdam, Netherlands


© Wensing et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.